MedTrace Logo

SOLX Titanium Sapphire Laser for Trabeculoplasty

NCT00145535 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2010-01-29

No results posted yet for this study

Summary

Use of the Titanium Sapphire laser for laser trabeculoplasty to reduce intraocular pressure in patients with poorly controlled intraocular pressure on maximally tolerated medical therapy or prior failed laser trabeculoplasty.

Conditions

Interventions

DEVICE

SOLX Titanium Sapphire Laser (TiSaLT)

Spot laser treatment, \~50 spots over 180°

DEVICE

Argon Laser Trabeculoplasty (ALT)

Spot laser treatment, \~50 spots over 180°

Sponsors & Collaborators

  • SOLX, Inc.

    lead INDUSTRY

Principal Investigators

  • Jan S Peterson, MS, RAC · The Emmes Company, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States
  • Canada
  • Israel
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00145535 on ClinicalTrials.gov